Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 17Fallopian Tube Neoplasms 17Carcinoma, Non-Small-Cell Lung 8Glioblastoma 7Carcinoma, Renal Cell 7Lung Neoplasms 6Colorectal Neoplasms 6Brenner Tumor 6Squamous Cell Carcinoma of Head and Neck 5Melanoma 5Uterine Cervical Neoplasms 4Triple Negative Breast Neoplasms 4Prostatic Neoplasms 4Gliosarcoma 4Breast Neoplasms 4Brain Neoplasms 4Recurrent Squamous Cell Lung Carcinoma 3Oligodendroglioma 3Neoplasm Metastasis 3Lymphoma, Large B-Cell, Diffuse 3Uveal Melanoma 2Urinary Bladder Neoplasms 2Spinal Cord Neoplasms 2Medulloblastoma 2Glioma 2Endometrial Adenocarcinoma 2Colonic Neoplasms 2Carcinoma 2Astrocytoma 2Adenocarcinoma of Lung 2

Interventions

Paclitaxel 2etoposide phosphate 1Taxes 1Platinum 1Immunoglobulin G 1Disulfides 1Cisplatin 1Carboplatin 1Bleomycin 1Bevacizumab 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Sertoli-Leydig Cell Tumor × Immunoglobulin G × Clear all
NCT00748657 2019-07-23

Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary

National Cancer Institute (NCI)

Phase 2 Completed
36 enrolled 7 charts
Gynecologic

Granulosa cell tumor of the ovary, Ovarian gynandroblastoma, Sertoli-Leydig Cell Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡